Latest Investments News

Viridis Mining has secured a non-binding Letter of Intent with Solvay to supply Mixed Rare Earth Carbonate from its Colossus Project, aiming for commercial production by 2028 and advancing Western-aligned rare earth supply chains.

Kelsian’s Transit Systems West has locked in a two-year extension for Sydney’s Region 6 bus services, adding $500 million in revenue and advancing its electric bus fleet rollout.

Aura Energy has secured a strategic non-binding MOU with a major international nuclear utility, underpinning funding and technical collaboration for its Tiris Uranium Project in Mauritania. The company has locked in a robust processing flowsheet and aims for a Final Investment Decision by the end of 2026.

WIN Metals has boosted its Radio Gold Project resource by 21% to 49,600 ounces at 4.2 g/t, underpinning plans for a near-term development decision backed by increased resource confidence and ongoing mining studies.

Revolver Resources has completed the detailed 3D earthworks and facilities design for its Dianne Copper Mine Project, advancing procurement for key processing equipment and edging closer to a Final Investment Decision.

AoFrio Limited has initiated a 1-for-7 renounceable rights offer at NZ$0.07 per share aiming to raise nearly NZ$5 million. This follows a recent $4.56 million placement and supports an aggressive growth strategy targeting $300 million revenue by 2030.

MFF Capital Investments’ May update shows a modest fall in net tangible assets per share and outlines a cautious yet optimistic portfolio stance amid geopolitical tensions and technological advances.

Intelligent Monitoring Group (ASX:IMB) has finalized its A$37 million purchase of Wormald NZ and Red Wolf, expanding its New Zealand footprint and projecting a 20.9% accretion in earnings per share.

ReadyTech Holdings has dismissed an unsolicited acquisition proposal valuing the company at $2.00 per share, calling it undervalued and unworkable. The offer includes a parallel off-market bid at $1.75 per share with a 50.1% minimum acceptance condition.

Paradigm Biopharmaceuticals has successfully raised $21.375 million through an oversubscribed Share Purchase Plan and a recent placement, bolstering its balance sheet ahead of key Phase 3 trial milestones.

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for eight of its Australian ETFs, detailing investment strategies, fees, risks, and operational protocols under ASX AQUA Rules.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.